Novartis has signed an agreement to purchase Myricx Bio, a UK-based biotechnology company, in a transaction valued at up to $1.5bn.

The US FDA has declined to approve Unicycive Therapeutics’ resubmitted NDA for OLC to treat hyperphosphatemia in CKD patients on dialysis.

Now, her ongoing alliance with a telehealth company may be signifying a broader shift in US healthcare advertising, reflecting a changing of the guard in celebrity endorsements. The 23-time Grand Slam ...

Children as young as two with either sickle cell disease or thalassemia are now eligible for the gene therapy.

Paris is emerging as a focal point for Europe’s next phase in oncology, as science, capital and industry converge at Campus Grand Parc.

The UK-US pharmaceuticals deal could cost the National Health Service (NHS) around £45bn ($60bn) within a decade and divert resources away from essential services, an analysis has suggested. The UK ...

The EC has granted approval for Novartis’ Itvisma as a treatment for children two years and older, teenagers, and adults who have 5q SMA with a bi-allelic mutation in the SMN1 gene.

Anthropic launches Claude Science as big tech companies increasingly eye expansion in the wider healthcare and life sciences space.

Sobi has received a CRL from the US FDA regarding its BLA for NASP, an investigational therapy intended for adults with uncontrolled gout.

SK bioscience is set to lead the Gates Foundation-funded ROTOR project, an AI-based platform aimed at reducing uncertainty in vaccine-development decisions.

WHO is sponsoring a trial testing drugs for Bundibugyo virus, while adding the first Ebola diagnostic test to its emergency use list.

Eli Lilly’s retatrutide has crossed the 30% weight loss benchmark in some patients. Where do GLP-1RAs go from here?